Prospective comparison of 3 γ-probes for sentinel lymph node detection in 200 breast cancer patients

被引:0
作者
Classe, JM
Fiche, M
Rousseau, C
Sagan, C
Dravet, F
Pioud, R
Lisbona, A
Ferrer, L
Campion, L
Resche, I
Curtet, C
机构
[1] Rene Gauducheau Canc Ctr, Dept Surg Oncol, St Herblain, France
[2] Hosp Laennec, Dept Histopathol, St Herblain, France
[3] Univ Laennec, St Herblain, France
[4] Rene Gauducheau Comprehens Canc Ctr, Dept Nucl Med, St Herblain, France
[5] Rene Gauducheau Canc Ctr, Dept Med Phys, St Herblain, France
[6] Rene Gauducheau Comprehens Canc Ctr, Dept Biostat, St Herblain, France
[7] INSERM, Unite 463, Nantes, France
关键词
breast cancer; sentinel lymph node; gamma-probe;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Previous reports have shown that axillary sentinel lymph node (ASLN) radiodetection allows accurate axillary staging for patients with early breast cancer. Radioguided surgery implies the use of a gamma-probe to count the emitted radioactivity of marked ASLNs. Several gamma-probes are commercially available, each with its own properties. The clinical impact of the type of gamma-probe used for ASLN radiodetection remains to be evaluated. Methods: Three commercially available gamma-probes were evaluated: a scintillator with a bismuth germanate crystal (probe A), a semiconductor with a cadmium telluride crystal (probe B), and a semiconductor with a cadmium zinc telluride crystal (probe C). Two hundred patients with early breast cancer were prospectively enrolled to undergo ASLN radiodetection and axillary lymphadenectomy. ASLN mapping consisted of injecting Tc-99m-sulfur-colloid around the tumor. For each patient, sentinel lymph nodes were counted successively with the 3 probes and the sensitivity of each gamma-probe was determined from ASLN residual activity. The results of detection rates and false-negative rates for each probe were compared. Results: Mean residual ASLN activity was 52 kBq (range, 0.07-189 kBq). Sensitivity was compared among the 3 probes and found to be best for probe A. The detection rate of probe A was significantly better than that of probe B (93% vs. 86%, P = 0.05) but not different from that of probe C (93% vs. 90%). No differences in false-negative rates were observed among the 3 probes. Conclusion: ASLN detection rate depends on the type of gamma-probe used. Because failure to detect the ASLN leads to complete axillary lymphadenectomy, involving local morbidity and other sequelae, the type of gamma-probe must be considered important for sentinel lymph node radiodetection.
引用
收藏
页码:395 / 399
页数:5
相关论文
共 32 条
  • [1] COMPARISON OF NAL(TL), CDTE, AND HGL2 SURGICAL PROBES - PHYSICAL CHARACTERIZATION
    BARBER, HB
    BARRETT, HH
    HICKERNELL, TS
    KWO, DP
    WOOLFENDEN, JM
    ENTINE, G
    BACCASH, CO
    [J]. MEDICAL PHYSICS, 1991, 18 (03) : 373 - 381
  • [2] Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer
    Bergkvist, L
    Frisell, J
    Liljegren, G
    Celebioglu, F
    Damm, S
    Thörn, M
    [J]. BRITISH JOURNAL OF SURGERY, 2001, 88 (12) : 1644 - 1648
  • [3] A method to evaluate intra-operative gamma probes for sentinel lymph node localisation
    Britten, AJ
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (02) : 76 - 83
  • [4] CABANAS RM, 1977, CANCER, V39, P456, DOI 10.1002/1097-0142(197702)39:2<456::AID-CNCR2820390214>3.0.CO
  • [5] 2-I
  • [6] Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer
    Ellis, P
    Smith, I
    Ashley, S
    Walsh, G
    Ebbs, S
    Baum, M
    Sacks, N
    McKinna, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 107 - 114
  • [7] GUILIANO AE, 1994, ANN SURG, V220, P391
  • [8] Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only:: A comparative evaluation
    Haid, A
    Köberle-Wührer, R
    Knauer, M
    Burtscher, J
    Fritzsche, H
    Peschina, W
    Jasarevic, Z
    Ammann, M
    Hergan, K
    Sturn, H
    Zimmermann, G
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 73 (01) : 31 - 36
  • [9] Accuracy of gamma probes in localizing radioactivity: In-vitro assessment and clinical implications
    Haigh, PI
    Glass, EC
    Essner, R
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (06) : 561 - 569
  • [10] Halkar R K, 1999, J Nucl Med Technol, V27, P188